No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis - 10/10/20
Doi : 10.1016/j.jaad.2020.06.012
Ulrich Mrowietz, MD, PhD a, Elisabeth Riedl, MD b, c, ⁎ 
, Stefan Winkler, MD, PhD d, Wen Xu, PhD c, Himanshu Patel, MD c, Noah Agada, MD c, Mark G. Lebwohl, MD e
, Stefan Winkler, MD, PhD d, Wen Xu, PhD c, Himanshu Patel, MD c, Noah Agada, MD c, Mark G. Lebwohl, MD e a Psoriasis Center, University Medical Center Schleswig-Holstein, Campus Kiel, Germany
b Department of Dermatology, Medical University of Vienna, Vienna, Austria
c Eli Lilly and Company, Indianapolis, Indiana, USA
d Department of Medicine I, Medical University of Vienna, Vienna, Austria
e Department of Dermatology, The Mount Sinai Hospital, New York, New York, USA
∗Correspondence to: Elisabeth Riedl, MD, PhD, Lilly International, Erdberger Laende 26a, 1030 Vienna, AustriaLilly InternationalErdberger Laende 26aVienna1030Austria
| Funding sources: Supported by Eli Lilly and Company (Indianapolis, IN, USA), which sponsored this study and provided medical writing (Elinor Wylde and Deirdre Elmhirst, Rx Communications) for this correspondence. |
|
| Disclosure: Dr Mrowietz has been an advisor and/or received speaker honoraria and/or received grants and/or contributed to clinical trials for the following companies: AbbVie, Almirall, Aristea, Boehringer Ingelheim, Celgene, Dr Reddy's, Eli Lilly, Foamix, Formycon, Forward Pharma, Janssen, Leo Pharma, Medac, Novartis, UCB, and Xenoport. Drs Riedl, Xu, Patel, and Agada are employees of Eli Lilly and Company. Dr Lebwohl is an employee of Mount Sinai who receives research funds from the following companies: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen/Johnson & Johnson, Kadmon, Leo Pharma, MedImmune, Novartis, Ortho Dermatologics, Pfizer, SciDerm, UCB, and Vidac and is a consultant for Allergan, Almirall, Arcutis, Avotres, Birch BioMed, Boehringer Ingelheim, Bristol Myers Squibb, Cara, Castle Biosciences, Dermavant, Encore, Inozyme, Leo Pharma, Meiji, Menlo, Mitsubishi Pharma, NeuroDerm Ltd, Pfizer, Promius/Dr Reddy's, Theravance Biopharma, and Verrica. Dr Winkler has no conflicts of interest to declare. |
|
| IRB approval status: N/A. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 5
P. 1436-1439 - novembre 2020 Retour au numéro
Article précédent
- Lack of association between chilblains outbreak and severe acute respiratory syndrome coronavirus 2: Histologic and serologic findings from a new immunoassay
- Vivien Hébert, Anne-Bénédicte Duval-Modeste, Pascal Joly, Véronique Lemée, Lucie Cellier, Fabienne Jouen, Benoit Veber, Laurent Drouot, Olivier Boyer
- Wound eversion versus planar closure for wounds on the face or neck: A randomized split-wound comparative effectiveness trial
- Claire C. Alexanian, Anne R. Zhuang, Milene K. Crispin, April W. Armstrong, Daniel B. Eisen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?